Sociedad Argentina de Terapia Radiante Oncológica

Best of ASTRO en Argentina

19 y 20 de Mayo de 2016
Hotel Melia Buenos Aires, Reconquista 945
Ciudad Autónoma de Buenos Aires
Jueves 19 de Mayo

08:00 – 18:00 hs. Inscripción

08:50 – 09:10 hs. Bienvenida

Comisión Directiva SATRO, Presidente Saliente: Dr. Ricardo Alva

Best of ASTRO Directora Dra. Luisa Rafailovici

Co-Director Dr. Eduardo Fernández

09:10 – 10:30 hs. **Módulo 1: Mama**

09:10 – 09:15 hs. **Presidente:** Dra. Verónica Vázquez Balcarce, Vidt Centro Médico, Bs As

**Moderador:** Dr. Hugo Marsiglia, Instituto Oncológico FALP, Chile

09:15 – 09:30 hs. **Dra. Luisa Rafailovici, Vidt Centro Médico, Buenos Aires**

| Abstract 1: (309) A Large Prospectively Designed Study of the DCIS Score: Recurrence Risk After Local Excision For Ductal Carcinoma In Situ Patients With and Without Irradiation |
| Abstract 2: (LBA7) Accelerated Partial Breast Irradiation Using Sole Interstitial Multicatheter Brachytherapy vs Whole Breast Irradiation for Early Breast Cancer: 5-year Results of a Randomized Phase III Trial – Part I: Local Control and Survival Results |
| Abstract 3: (131) Acute Toxicity and Quality of Life of Hypofractionated Radiation Therapy for Breast Cancer |

09:30 – 09:50 hs. **Dra. Silvia Zunino, Instituto Marie Curie, Córdoba**

| Abstract 4: (132) Long-term Toxicity and Outcomes of Hypofractionated Radiation Therapy With an Incorporated Boost for Early-Stage Breast Cancer |
| Abstract 5: (130) NRG Oncology/RTOG 1014: 1-Year Toxicity Report From a Phase II Study of Repeat Breast Preserving Surgery and 3D Conformal Partial-Breast Re-irradiation (PBrI) for In-Breast Recurrence |
| Abstract 6: (1165) Loco-regional Failure Rates Are Low After Mastectomy in a Modern Cohort of Patients with T1-T2 Tumors With 1-3 Pathologically Involved Lymph Nodes |
| Abstract 7: (241) Impact of Ipsilateral Blood Pressure Measurements, Blood Draws, Infusions, and Air Travel on the Risk of Lymphedema for Patients Treated for Breast Cancer: A Prospective Study |

09:50 – 10:30 hs. **Mesa de Discusión**

**Moderador:** Dr. Hugo Marsiglia

Dra. Verónica Vázquez Balcarce

Dra. Luisa Rafailovici, Dra. Silvia Zunino

Dr. Gonzalo Recondo, CEMIC, Buenos Aires

Dr. Pedro Kasdorf, Instituto Nacional del Cáncer, Montevideo, Uruguay

Dr. Aníbal Núñez De Pierro, Sanatorio Mater Dei, Buenos Aires
Jueves 19 de Mayo

10:30 – 11:10 hs. **Módulo 2: Física**

10:30 – 10:35 hs. **Presidente:** Ing. Víctor Suarez, Vidt Centro Médico, Buenos Aires

10:35 – 11:10 hs. **Disertante y Comentarios:**

Lic. Víctor Bourel, Universidad Favaloro, Buenos Aires

<table>
<thead>
<tr>
<th>Abstract 1: (90)</th>
<th>Response Assessment with Serial Diffusion Weighted Magnetic Resonance Imaging During Chemoradiation Therapy for Non-Small Cell Lung Cancer: A Pilot Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstract 2: (96)</td>
<td>Dose-Response Relationship for Stereotactic Ablative Body Radiation Therapy Associated Airway Collapse</td>
</tr>
<tr>
<td>Abstract 3: (95)</td>
<td>Effects of Gold Nanoparticles for Radiation Therapy Enhancement</td>
</tr>
<tr>
<td>Abstract 4: (88)</td>
<td>Validation of a Knowledge-Based Automated Planning System in Cervical Cancer As a Clinical Trial Quality System</td>
</tr>
<tr>
<td>Abstract 5: (9)</td>
<td>Radiomic Analysis of FDG-PET Identifies Novel Prognostic Imaging Biomarkers in Locally Advanced Pancreatic Cancer Patients Treated With SBRT</td>
</tr>
</tbody>
</table>

11:10 – 11:40 hs. **Intervalo Café**
Jueves 19 de Mayo

11:40 – 13:05 hs. **Módulo 3: Pulmón**

11:40 – 11:45 hs. **Presidente:** Dr. Aldo Quarneti, Hospital Británico, Montevideo, Uruguay

**Moderadora:** Dra. Berta Roth, Instituto Ángel Roffo, Buenos Aires

**Disertantes:**

11:45 – 12:05 hs. **Dra. María Luisa Filomia, Vidi Centro Médico, Buenos Aires**

- Abstract 1: (196) Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non Small Cell Lung Cancer: CALGB 31102 (Alliance)
- Abstract 2: (2) Comparison of 3-D Conformal and Intensity Modulated Radiation Therapy Outcomes for Locally Advanced Non-Small Cell Lung Cancer in NRG Oncology/RTOG 0617
- Abstract 3: (149) Abscopal Responses in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Treated on a Phase 2 Study of Combined Radiation Therapy and Ipilimumab: Evidence for the In Situ Vaccination Hypothesis of Radiation
- Abstract 4: (150) The Lung Metastasis Risk (LMR) Signature: A Prognostic Genomic Biomarker Predicting Distant Failure Among Stage I Adenocarcinoma Patients Following Local Therapy

12:05 – 12:25 hs. **Dr. Gustavo Ferraris, Centro Médico Dean Funes, Córdoba**

- Abstract 5: (228) Predicting Overall Survival Following Stereotactic Ablative Radiation Therapy in Early-Stage Lung Cancer: Development and External Validation of the Amsterdam Prognostic Model
- Abstract 6: (229) Prospective Phase 2 Clinical Trial of Radiation Dose Escalated Stereotactic Body Radiation Therapy (SBRT) for Centrally Located Lung Cancer: An Institutional Trial
- Abstract 7: (LBA 9) NRG Oncology/RTOG 0937: Randomized Phase II Study Comparing Prophylactic Cranial Irradiation (PCI) Alone To PCI and Consolidative Extra-Cranial Irradiation For Extensive Disease Small Cell Lung Cancer (ED-SCLC)
- Abstract 8: (LBA10) Primary Study Endpoint Analysis for NRG Oncology/RTOG 0813 Trial of Stereotactic Body Radiotherapy (SBRT) for centrally located non small cell lung cancer (NSCLC)

12:25 – 13:05 hs. **Mesa de Discusión / Presentación de casos**

**Moderador:** Dra. Berta Roth

Dr. Aldo Quarneti, Dra. María Luisa Filomia, Dr. Gustavo Ferraris
Dr. Claudio Martín, Instituto Alexander Fleming, Buenos Aires
Dr. Carlos Pizzo, Terapia Radiante Cumbres, Rosario, Sta. Fe

13.05 – 14:30 hs. **Almuerzo Libre**
Jueves 19 de Mayo

14:30 – 15:55 hs. **Módulo 4: Cuidados Paliativos**

14:30 – 14:35 hs. **Presidente:** Dr. Hernán Castro Vita, Centro Méd. Dean Funes, Córdoba

**Moderador:** Dr. Eduardo Fernández, 21st Century Oncology, USA

**Disertantes:**

14:35 – 14:55 hs. **Dr. Jorge Sar, Centro de Radioterapia, Rio Cuarto, Córdoba**

<table>
<thead>
<tr>
<th>Abstract 1: (137) Palliative Care Training in Radiation Oncology: A National Survey</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstract 2: (138) Comparison of Patient Reported Outcomes With Single Versus Multiple Fraction Palliative Radiation Therapy for Complicated Bone Metastasis</td>
</tr>
<tr>
<td>Abstract 3: (3177) Incidence and Treatment Patterns of Complicated Bone Metastases in a Population-Based Radiation Therapy Program</td>
</tr>
<tr>
<td>Abstract 4: (136) The Impact of Dynamic Changes to a Bone Metastases Pathway in a Large Integrated National Cancer Institute Designated Comprehensive Cancer Center Network</td>
</tr>
</tbody>
</table>

14:55 – 15:15 hs. **Dr. Carlos Donosso, Hospital Austral, Buenos Aires**

<table>
<thead>
<tr>
<th>Abstract 5: (140) Efficacy of Spine Radiosurgery for Oligometastatic Spine Disease: A Large Institutional Experience</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstract 6: (141) Impact of a Dedicated Palliative Radiation Oncology Service on the Use of Single-Fraction and Hypofractionated Radiation Therapy Among Patients With Bone Metastases</td>
</tr>
<tr>
<td>Abstract 7: (142) Long-term Survivors of an SBRT Dose-Escalation Study for Oligometastases: Clinical and Molecular Markers</td>
</tr>
<tr>
<td>Abstract 8: (3207) Outcomes After Whole-Brain Reirradiation for Multiple Brain Metastases: Total Dose Is Associated With Improved Overall Survival</td>
</tr>
</tbody>
</table>

15:15 – 15:55 hs. **Mesa de Discusión / Presentación de casos**

**Moderador:** Dr. Eduardo Fernández

Dr. Hernán Castro Vita, Dr. Jorge Sar, Dr. Carlos Donosso

Dra. Graciela Jacob, Médica Master en Medicina y Cuidados Paliativos

Dr. Marcelo Blanco Villalba, Centro Médico Austral, Buenos Aires

Dr. Eduardo Weltman, Hospital Israelita Albert Enstein, San Pablo, Brasil
Jueves 19 de Mayo

15:55 – 16:35  **Modulo 5: Seguridad del Paciente**

15:55 – 16:00 hs.  **Presidente:** Lic. María del Pilar Duran, Vidt Centro Médico, Buenos Aires

**Moderador:** Lic. Karla Torzsok, Instituto Oncológico FALP, Chile

**Disertantes:**

16:00 – 16:25 hs.  **Lic. Liliana Mairal, Centro Médico Mevaterapia, Buenos Aires**

<table>
<thead>
<tr>
<th>Abstract 1:</th>
<th>(33) Results of Voluntary Error Reporting in Radiation Oncology Treatment Delivery From a Multi-practice Setting From 2005 to 2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstract 2:</td>
<td>(34) A Validated Nomogram to Predict Near Miss and Safety Incidents in Radiation Oncology: A Multi-institutional Effort</td>
</tr>
<tr>
<td>Abstract 3:</td>
<td>(39) Data-driven Management Using Quantitative Metric and Automatic Auditing Program (QMAP) Leads to Significant and Sustained Improvement of Consistency of Radiation Oncology Processes</td>
</tr>
<tr>
<td>Abstract 4:</td>
<td>(32) Validation of a Causal Factor Taxonomy Used in Radiation Oncology Incident Learning</td>
</tr>
<tr>
<td>Abstract 5:</td>
<td>(37) A Quantitative Assessment of the Utility of Safety Barriers</td>
</tr>
</tbody>
</table>

16:25 – 16:35 hs.  **Comentarios Módulo Seguridad del Paciente**

Lic. Karla Torzsok

16:35 – 17:05 hs.  **Intervalo Café**
Jueves 19 de Mayo

17:05 – 18:15 hs.  Módulo 6: Linfoma / Leucemia

17:05 – 17:10 hs.  Presidente: Dr. Ricardo Alva, Hospital Naval, Buenos Aires

Moderador:
Dr. Mario Di Nucci,
Centro de Oncología y Radioterapia, Mar del Plata, Pcia. Bs. As.

Disertantes:
17: 10 – 17:20 hs.  Dra. Patricia Bruno
Centro de Oncología y RT, V. María, Córdoba


Abstract 2: (181) Does the Risk of Cardiovascular Disease Plateau Following Mediastinal Irradiation: A Review of Hodgkin Lymphoma Survivors With Over 30 Years of Follow-up

17-20 – 17:40 hs.  Dr. Juan José Galarraga,
Centro de Oncología y RT, Mar del Plata, Pcia. Bs. As.

Abstract 3: (179) Predictors of Radiation Pneumonitis in Patients Receiving Intensity Modulated Radiation Therapy for Hodgkin and Non Hodgkin Lymphoma

Abstract 4: (147) Role of Consolidative Radiation Therapy Following Autologous Stem Cell Transplant for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Abstract 5: (145) Risk-adapted Radiation Therapy Improves Survival of Early-Stage Extra-nodal Nasal-Type NK/T Cell Lymphoma: A Comprehensive Analysis from a Multicenter Study

Abstract 6: (144) What Is the Optimal Definition of Bulk in DLBCL Patients Treated With RCHOP?

17:40 – 18:00 hs.  Dr. Óscar Gómez Orrego
ALCEC, Concepción Uruguay, E. Ríos

Abstract 7: (148) Patterns of Care and Survival Outcomes Examining Radiation Therapy for Advanced Hodgkin Lymphoma

Abstract 8: (184) Early-stage Nodular Lymphocyte-Predominant Hodgkin Lymphoma: The Impact of Radiation Therapy on Overall Survival

Abstract 9: (183) Early-Stage, Low-Grade Follicular Lymphoma: How Much Evidence Do We Need to Adopt Radiation Therapy as the Primary Treatment?

Abstract 10: (186) Outcomes After Chemotherapy Followed by Radiation for Stage IIB Hodgkin Lymphoma With Bulky Disease

18:00 – 18:15 hs.  Comentarios Módulo Linfoma / Leucemia
Dr. Mario Di Nucci
Jueves 19 de Mayo

18:15 – 19:15 hs. **Sesión Educacional**
Rectal Cancer Clinical Practice Statement: One Size Does Not Fit All

18:15 – 18:20 hs. **Presidente:** Dr. Miguel Torres, Centro C.O.R., Montevideo, Uruguay

**Disertantes:**
18:20 – 18:40 hs. Dr. Eduardo Huertas, Instituto Alexander Fleming, Buenos Aires
(Perspectiva del Cirujano Oncólogo)

18:40 – 19:00 hs. Dra. María Fernanda Díaz Vázquez
Centro Médico Dean Funes, Córdoba
(Perspectiva del Radio-Oncólogo)

19:00 – 19:15 hs. Preguntas del público
Viernes 20 de Mayo

08:00 – 12:00 hs.  Inscripción

09:00 – 10:25 hs.  Módulo 7: Cabeza y Cuello

09:00 – 9:05 hs.  Presidente: Dra. Cecilia Coll, Instituto de Radioterapia Cuyo, Mendoza

Moderador: Dr. Marcos David Pereira, Instituto Ángel Roffo, Buenos Aires

Disertantes:

09:05 – 09:25 hs.  Dr. Carlos Cardiello, Hospital Militar, Buenos Aires

Abstract 1: (171) Comparing the Survival, Recurrence, and Toxicities Between Surgery With Adjuvant Therapy Versus Surgery Alone for Human Papillomavirus–Positive Oropharyngeal Squamous Cell Carcinoma

Abstract 2: (172) Cetuximab-based Bioradiation Therapy Is Associated With Higher Rates of Distant Metastases Than Platinum-based Chemoradiation Therapy in Human Papillomavirus–Positive Oropharyngeal Cancer

Abstract 3: (170) High E6 Gene Expression Predicts for Distant Metastasis and Cancer-Specific Survival in Patients With HPV-Positive Oropharyngeal Squamous Cell Carcinoma

Abstract 4: (297) Risk Stratification for Relapse in Human Papillomavirus–Unrelated Oropharyngeal Carcinoma Treated With Definitive Radiation Therapy With or Without Chemotherapy

09:25 – 09:45 hs.  Dr. Jorge Palazzo, Vidt Centro Médico, Tucumán

Abstract 5: (292) The Value of Adding Chemotherapy to Intensity Modulated Radiation Therapy for Stage II Nasopharyngeal Carcinoma: A Multicenter Phase 2 Study

Abstract 6: (295) Radiation Plus Concurrent Nimotuzumab Versus Cisplatin-Based Chemotherapy in Locally Advanced Nasopharyngeal Cancer: An Interim Analysis of a Phase 3 Randomized Clinical Trial

Abstract 7: (161) Individualized Super Selective Nodal Radiation Therapy for cN0 Head and Neck Squamous Cell Carcinoma Patients Based on Sentinel Node(s) Identification: A Prospective Phase 2 Study of SPECT/CTguided volume de-escalation

Abstract 8: (291) Impact of Radiation Oncologist Provider Volume on Clinical Outcomes in Head and Neck Cancer

09:45 – 10:25 hs.  Mesa de Discusión / Presentación de casos

Moderador: Dr. Marcos David Pereira
Dra. Cecilia Coll, Dr. Carlos Cardiello, Dr. Jorge Palazzo
Dr. Pedro Saco, Hospital Austral, Buenos Aires
Dr. Raúl Giglio, Instituto Ángel Roffo, Buenos Aires
Dr. Nicholas Reñe, Centro de Radioterapia, Rosario, Provincia de Sta. Fe
Viernes 20 de Mayo

10:25 – 11:55 hs. **Módulo 8: Genitourinario**

10:25 – 10:30 hs. **Presidente:** Dr. Jorge Chiozza, Vidt Centro Médico, Buenos Aires

**Moderador:** Dra. Carolina Chacon, Instituto Alexander Fleming, Bs. As.

**Disertantes:**

10:30 – 10:45 hs. **Dr. Eduardo Fernández, 21st Century Oncology, USA**

- Abstract 1: (4) Quality of Life Outcomes: ASCENDE-RT * a Multicentre Randomized Trial of Radiation Therapy for Prostate Cancer
- Abstract 2: (LBA 6) NRG Oncology RTOG 0415: A Randomized Phase III Non-Inferiority Study Comparing Two Fractionation Schedules in Patients with Low-Risk Prostate Cancer
- Abstract 3: (97) Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG Oncology/RTOG 9202

10:45 – 11:00 hs. **Dra. Carmen Castro, Hospital Alemán, Buenos Aires**

- Abstract 4: (102) Is There a Role for Pelvic Irradiation in Localized Prostate Adenocarcinoma: Final Results of the European Groupe d'Etude des Tumeurs Uro-Génitales (GETUG-01) Randomized Study
- Abstract 5: (300) Contemporary Update of a Multi-institutional Predictive Nomogram for Salvage Radiation Therapy After Prostatectomy
- Abstract 6: (LBA 5) Report of NRG Oncology/RTOG 9601, A Phase III Trial in Prostate Cancer: Anti-androgen Therapy (AAT) with Bicalutamide During and After Radiation Therapy (RT) in Patients Following Radical Prostatectomy (RP) with pT2-3pN0 Disease and an Elevated PSA

11:00 – 11:15 hs. **Dra. Carolina Chacon, Instituto Alexander Fleming, Bs. As.**

- Abstract 7: (306) Validation of a Genomic Classifier for Prediction of Metastasis Following Postoperative Salvage Radiation Therapy
- Abstract 8: (49) Long-term Outcomes After Bladder-Preserving Combined Modality Therapy for Patients With Muscle-Invasive Bladder Cancer
- Abstract 9: (56) Management and Outcomes of Clinical Stage II A/B Seminoma: Results From the National Cancer Data Base

11:15 – 11:55 hs. **Mesa de Discusión / Presentación de casos**

**Moderador:** Dra. Carolina Chacon
Dr. Jorge Chiozza, Dr. Eduardo Fernández,
Dra. Carmen Castro, Dra. Carolina Chacon
Dr. Luis Montes de Oca, CDU, Buenos Aires
Dr. Carlos Scorticati, Hospital de Clínicas, Buenos Aires

11:55 – 12:25 hs. **Intervalo Café**
Viernes 20 de Mayo

12:25 – 13:50  **Módulo 9: Gastrointestinal**

**12:25 – 12:30 hs.**  **Presidente:** Dr. Andrés Salum, Centro de Oncologia Radiante, Jujuy

**Moderador:**
Dra. Higinia Cardenes, Radiation Oncology Indianapolis, USA

**Disertantes:**

**12:30 – 12:45 hs.**  **Dr. Luis Reñé, Centro de Radioterapia, Rosario, Santa Fe**

Abstract 1: (7) *Involved-field Irradiation vs Elective Nodal Irradiation for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: A Comparative Interim Analysis of Clinical Outcomes and Toxicities (NCT01551589, CSWOG 003)*

Abstract 2: (29) *Phase 2 Study of Simultaneous Modulated Accelerated Radiation Therapy Combined With Chemotherapy for Esophageal Squamous Cell Carcinoma: Early Outcomes*

Abstract 3: (254) *A Single Arm Phase 2 Study of Individualized Proton-Based Stereotactic Body Radiation Therapy (P-SBRT) of Liver Metastases*

**12:45 – 13:00 hs.**  **Dra. Claudia Benavento, Hospital B. Rivadavia, Buenos Aires**

Abstract 4: (287) *Pathological Response Is a Marker But Not a Cause of Good Prognosis in Rectal Cancer: 15-year Follow-up of the Lyon R90-01 Randomized Trial*

Abstract 5: (289) *Phase 2 Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab. in Patients With Locally Advanced Rectal Cancer: ECOG 3204*

Abstract 6: (290) *Preoperative Chemoradiation With a Simultaneous Integrated Boost Compared to Regular Preoperative Chemoradiation for Locally Advanced Rectal Cancer: Interim Analysis of a Randomized Phase 2 Trial (NCT02195141)*

**13:00 – 13:10 hs.**  **Dr. Gastón Lemoine, Instituto de Radiaciones, Salta**

Abstract 7: (350) *Prospective and Concurrent Analysis of Postresection CA19-9 Level and Surgical Margin Status (SMS) as Predictors of Pattern of Disease Recurrence Following Adjuvant Treatment for Pancreatic Carcinoma: NRG Oncology/RTOG 9704 Secondary Analysis*

Abstract 8: (351) *Favorable Perioperative and Survival Outcomes After Resection of Borderline Resectable Pancreatic Cancer Treated With Neoadjuvant Stereotactic Radiation and Chemotherapy Compared With Upfront Pancreatectomy for Resectable Cancer*

**13:10 – 13:50 hs.**  **Mesa de Discusión / Presentación de casos**

**Moderador:** Dr. Higinia Cardenes
Dr. Andrés Salum, Dra. Claudia Benavento, Dr. Luis Reñé, Dr. Gastón Lemoine
Dr. Eduardo Huertas, Instituto Alexander Fleming, Buenos Aires
Dr. Mario Barugel, Hospital de Gastroenterología B. Udaondo, Bs.As.

**13:50 – 14:20 hs.**  **Conferencia Varian**

Dr. Eduardo Weltman “Aria como Sistema de Información Oncológica”

**14:20 – 15:20 hs.**  **Lunch – Invitación SATRO**
Viernes 20 de Mayo

15:20 – 16:45 hs. **Módulo 10: Ginecológico**

15:20 – 15:25 hs. **Presidente:**
Dra. Estela Broda, Vidt Centro Médico, Buenos Aires

**Moderador:**
Dra. Higinia Cardenes, Radiation Oncology Indianapolis, USA

**Disertantes:**

15:25 – 15:40 hs. **Dr. Pablo Menéndez, Instituto Ángel Roffo, Bs. As.**

Abstract 1: 8) Phase III RCT of Postoperative Adjuvant Conventional Radiation Therapy (3DCRT) Versus IGIMRT for Reducing Late Bowel Toxicity in Cervical Cancer (PARCER) (NCT01279135/CTRI2012/120349): Results of Interim Analyses

Abstract 2: (17) Adjuvant Intensity Modulated Radiation Therapy With Concurrent Paclitaxel and Cisplatin in Cervical Cancer Patients With High Risk Factors: A Phase 2 Trial

Abstract 3: (18) Distant Metastases in Locally Advanced Cervical Cancer Pattern of Relapse and Prognostic Factors: Early Results From the EMBRACE Study


Abstract 4: (19) Salvage Versus Adjuvant Radiation Treatment for Women With Early-Stage Endometrial Carcinoma: A Matched Analysis

Abstract 5: (21) Metformin Use Is Associated With Lower Cervical Cancer–Specific Mortality

Abstract 6: (22) Early Risk Assessment by FDG-PET Textural Analyses for Patients With Bulky Cervical Cancer

15:55 – 16:05 hs. **Dr. Federico Díaz, Instituto Mevaterapia, Buenos Aires**

Abstract 7: (23) Adjuvant External Radiation is Essential in the Management of Pelvis-Limited Stage III Endometrial Carcinoma

Abstract 8: (24) Impact of Hyperglycemia in Patients With Cervical Cancer Treated With Definitive Chemoradiation on Overall Survival and Locoregional Control

16:05 – 16:45 hs. **Mesa de Discusión / Presentación de casos**

**Moderador:** Dra. Higinia Cardenes
Dra. Estela Broda, Dr. Pablo Menéndez,
Dra. Lijia Aviles, Dr. Federico Díaz
Dra. MaríA Eugenia Gamboa, Sociedad de Radioterapia, Bolivia
Dra. Perrota Myriam, Hospital Italiano, Buenos Aires
Dra. Florencia Perazzo, CEMIC, Buenos Aires
Viernes 20 de Mayo

16:45 – 18:10  **Módulo 11: Sistema Nervioso Central**

16:45 – 16:50  **Presidente:** Dra. Mabel Sardi, Instituto Mevaterapia, Buenos Aires

**Moderador:** Dr. Eduardo Weltman  
Hospital Israelita Albert Enstein, San Pablo, Brasil

**Disertantes:**

16:50 – 17:10 hs.  **Dr. Máximo Barros, Hospital Interzonal Profesor Dr. Luis Güemes, Haedo, Pcia. de Buenos Aires**

<table>
<thead>
<tr>
<th>Abstract 1: (83) Effect of Gene Mutations on Survival in Patients With Adenocarcinoma of the Lung Following the Development of Brain Metastases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstract 2: (84) A Phase I/II Dose-Escalation Trial of 3-Fraction Stereotactic Radiosurgery (SRS) for Large Resection Cavities of Brain Metastases</td>
</tr>
<tr>
<td>Abstract 3: (85) Comparing Preoperative Stereotactic Radiosurgery (SRS) to Postoperative SRS for Resectable Brain Metastases</td>
</tr>
<tr>
<td>Abstract 4: (124) International Consensus on Contouring Guidelines for Postoperative Spine Stereotactic Body Radiation Therapy (SBRT)</td>
</tr>
</tbody>
</table>

17:10 – 17:30 hs.  **Dra. Ana Mabel Martínez, Vidt Centro Médico, Buenos Aires**

<table>
<thead>
<tr>
<th>Abstract 5: (247) Delayed Contrast MRI for Differentiating Brain Tumors From Treatment Effects in Conventional and Combined Treatments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstract 6: (248) A Phase 2 Study of Temozolomide in the Treatment of Adult Patients With Supratentorial Low-grade Glioma</td>
</tr>
<tr>
<td>Abstract 7: (317) Intermediate-risk Meningioma: Initial Outcomes from NRG Oncology/RTOG-0539</td>
</tr>
<tr>
<td>Abstract 8: (318) Stereotactic Radiation Therapy and the Management of Atypical Meningiomas: Outcomes in the Upfront and Recurrent Setting</td>
</tr>
</tbody>
</table>

17:30 – 18:10 hs.  **Mesa de Discusión / Presentación de caso**

**Moderador:** Dr. Eduardo Weltman  
Dra. Mabel Sardi, Dra. Ana Mabel Martínez, Dr. Máximo Barros  
Dr. Ignacio Sisamon, Centro de Oncol. y RT, Mar del Plata, Bs As  
Dra. Blanca Diez, “Fleni” Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia, Buenos Aires  
Dr. Diego Hernández, Hospital Naval, Buenos Aires

18:10 – 18:40 hs.  **Intervalo Café**
**Viernes 20 de Mayo**

**18:40 – 19:20  Módulo 12: Biología**

18:40 – 18:45 hs. **Presidente:** Dr. Enzo Marinello, Hospital San Luis, Pcia. de San Luis  
**Moderador:** Dra. Mabel Sardi, Instituto Mevaterapia, Buenos Aires  
**Disertantes:**

18:45 – 18:55 hs. **Dra. Alba Güerci, Universidad Nacional de la Plata, Bs. As.**  
Abstract 1: (325) High-throughput Transcriptomic Analysis Nominates Proteasomal Genes as Age Specific Biomarkers and Therapeutic Targets in Prostate Cancer  
Abstract 2: (235) Radiation Induced CD8 T-Lymphocyte Apoptosis As a Predictor of Late Toxicity After Radiation Therapy: Results of the Prospective Multicenter French Trial

Abstract 3: (162) Mutational Analysis of Ionizing Radiation Induced Neoplasms  
Abstract 4: (326) Systematic Investigation of Genetic Vulnerabilities Across Cancer Cell Lines Reveals Lineage Specific Radiotherapeutic Determinants  
Abstract 5: (6) Response, Resistance Mechanisms, and Biomarkers for Radiation and Immune Checkpoint Blockade

19:10 – 19:20 hs. **Comentarios Módulo Biología**  
Dra. Mabel Sardi

19:20 – 19:50 hs. **Cierre del Evento con acto de Entrega de Diplomas de Recertificación en Radioterapia**